About Intignus Biotech
Intignus Biotech is a company based in Pune (India) founded in 2018 by Vaishnavi Kulkarni. Intignus Biotech has raised $288.89 thousand across 3 funding rounds from investors including Indian Institute of Technology Kanpur, Jitendra Tanna and Ravi Nigam. Intignus Biotech offers products and services including Preeclampsia Screening Test. Intignus Biotech operates in a competitive market with competitors including Beikang Medical, Droplet Health, Valeo Medical, Heranova Lifesciences and Sofiva Genomics, among others.
- Headquarter Pune, India
- Founders Vaishnavi Kulkarni
- Stage Minicorn
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Intignus Biotech Private Limited
- Date of Incorporation 26 Jun, 2018
- Jurisdiction Pune, Maharashtra, India
-
Annual Revenue
$23.96 K (USD)7.69as on Mar 31, 2022
-
Net Profit
-$9.36 K (USD)25.42as on Mar 31, 2022
-
EBITDA
-$23.44 K (USD)-8.83as on Mar 31, 2022
-
Total Equity Funding
$288.89 K (USD)
in 3 rounds
-
Latest Funding Round
$248.2 K (USD), Seed
Feb 16, 2023
- Investors
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Intignus Biotech
Intignus Biotech offers a comprehensive portfolio of products and services, including Preeclampsia Screening Test.
Test for early detection of preeclampsia in pregnant women.
Funding Insights of Intignus Biotech
Intignus Biotech has successfully raised a total of $288.89K across 3 strategic funding rounds. The most recent funding activity was a Seed round of $248.2 thousand completed in February 2023. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Intignus Biotech
Intignus Biotech has secured backing from 6 investors, including angel, institutional, and venture fund investors. Prominent investors backing the company include Indian Institute of Technology Kanpur, Jitendra Tanna and Ravi Nigam.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Startups are incubated at Venture Center, backed by CSIR.
|
Locked | Locked | Locked | |
|
Support is extended to innovators and entrepreneurs by the foundation.
|
Locked | Locked | Locked | |
|
Multiple engineering courses and degrees are offered at the institute.
|
Locked | Locked | Locked |
Investor details for Intignus Biotech
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Intignus Biotech
Investment portfolio details for Intignus Biotech
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Intignus Biotech
Detailed financials for Intignus Biotech
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Intignus Biotech Comparisons
Peer comparison for Intignus Biotech
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Intignus Biotech
Intignus Biotech operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Beikang Medical, Droplet Health, Valeo Medical, Heranova Lifesciences and Sofiva Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
NGS-based diagnostic solutions for neonatal screening are developed.
|
|
| Locked | Locked | Locked |
Home-based kits for women's menstrual health diagnostics are provided.
|
|
| Locked | Locked | Locked |
Developing a non-invasive blood test for endometriosis diagnosis.
|
|
| Locked | Locked | Locked |
Developing diagnostics and treatments for womens health
|
|
| Locked | Locked | Locked |
Provides prenatal and neonatal genetic screening tests for accurate health assessments.
|
Detailed competitors of Intignus Biotech
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Intignus Biotech
Complete news archive for Intignus Biotech
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Intignus Biotech
Intignus Biotech was founded in 2018 and raised its 1st funding round 1 year after it was founded.
Intignus Biotech is headquartered in Pune, India. It is registered at Pune, Maharashtra, India.
Vaishnavi Kulkarni is the current CEO of Intignus Biotech. They have also founded this company.
Intignus Biotech is a funded company, having raised a total of $288.89K across 3 funding rounds to date.
Annual revenue of Intignus Biotech is $23.96K as on Mar 31, 2022.
Intignus Biotech was founded in 2018 and is based in Pune, India, within the biotechnology sector. In-vitro diagnostic devices for early detection of pregnancy-related conditions, including preeclampsia and premature labor, are produced. Prenatal genetic screening tests are offered to assess maternal and fetal health. Cell culture services are provided for research applications.
Intignus Biotech's top competitors include Beikang Medical, Heranova Lifesciences and Droplet Health.
Intignus Biotech offers Preeclampsia Screening Test.
Intignus Biotech has 6 investors. Key investors include Indian Institute of Technology Kanpur, Jitendra Tanna, Ravi Nigam, Vivek Gupta, and Innovators & Entrepreneurs Foundation.
The valuation of Intignus Biotech is $1.13M as of Feb 2023.